An Observational Study to Evaluate the Effect of L-ornithine L-aspartate in Patients With Overt Hepatic Encephalopathy Receiving Lactulose and Rifaximin

In this study, we observed that administering LOLA in conjunction with standard background therapy has significantly improved the grade of HE, as determined by the West Haven scoring system. Fasting serum ammonia levels, LFT parameters, and quality of life as per SF-36 also improved in the group that received LOLA. Thus, the addition of LOLA to the first-line standard therapy was found to be effective and might help in improving the clinical grade of HE.